1. Home
  2. MDGL vs PDI Comparison

MDGL vs PDI Comparison

Compare MDGL & PDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • PDI
  • Stock Information
  • Founded
  • MDGL 2011
  • PDI 2012
  • Country
  • MDGL United States
  • PDI United States
  • Employees
  • MDGL N/A
  • PDI N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • PDI Trusts Except Educational Religious and Charitable
  • Sector
  • MDGL Health Care
  • PDI Finance
  • Exchange
  • MDGL Nasdaq
  • PDI Nasdaq
  • Market Cap
  • MDGL 6.1B
  • PDI 7.3B
  • IPO Year
  • MDGL N/A
  • PDI N/A
  • Fundamental
  • Price
  • MDGL $414.68
  • PDI $19.30
  • Analyst Decision
  • MDGL Strong Buy
  • PDI
  • Analyst Count
  • MDGL 8
  • PDI 0
  • Target Price
  • MDGL $445.71
  • PDI N/A
  • AVG Volume (30 Days)
  • MDGL 469.6K
  • PDI 1.5M
  • Earning Date
  • MDGL 08-05-2025
  • PDI 01-01-0001
  • Dividend Yield
  • MDGL N/A
  • PDI 13.81%
  • EPS Growth
  • MDGL N/A
  • PDI N/A
  • EPS
  • MDGL N/A
  • PDI N/A
  • Revenue
  • MDGL $515,547,000.00
  • PDI N/A
  • Revenue This Year
  • MDGL $286.67
  • PDI N/A
  • Revenue Next Year
  • MDGL $67.98
  • PDI N/A
  • P/E Ratio
  • MDGL N/A
  • PDI N/A
  • Revenue Growth
  • MDGL 3421.98
  • PDI N/A
  • 52 Week Low
  • MDGL $200.63
  • PDI $15.45
  • 52 Week High
  • MDGL $419.99
  • PDI $19.60
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 77.54
  • PDI 62.17
  • Support Level
  • MDGL $351.32
  • PDI $19.06
  • Resistance Level
  • MDGL $393.76
  • PDI $19.38
  • Average True Range (ATR)
  • MDGL 17.32
  • PDI 0.07
  • MACD
  • MDGL 6.15
  • PDI -0.00
  • Stochastic Oscillator
  • MDGL 94.95
  • PDI 72.73

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About PDI PIMCO Dynamic Income Fund

PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investments include mortgage-backed securities, investment grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.

Share on Social Networks: